A Retrospective Study: Evaluation of the Efficacy of Immunotherapy With Rare Mutations in Non-small Cell Lung Cancer
Recruiting · NCT04777175 · Observational (researchers observe without assigning treatment)
View the official record on ClinicalTrials.gov →Interventions studied
immunity therapy
What this trial is about
In advanced non-small cell lung cancer, there will be some rare mutations, such as ALK, KRAS, etc. The efficacy of these immunotherapies on these different rare mutations has not been reported. Therefore, we conducted this retrospective clinical study to explore the efficacy of immunotherapy for different rare mutations.
Who can take part
Age range
18 Years to 75 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- 1.Diagnosed as advanced non-small cell lung cancer
- 2.Confirmed as KARS, ALK, ERBB2, MET, RET, BRAF mutation
Exclusion criteria
- The patient is diagnosed with small cell lung cancer
Where it is running
2 locations listed.
- Hunan Cancer Hospital - Changsha, Hunan, China
- Hunan Cancer hospital - Changsha, Hunan, China